MindRank’s oral GLP-1 is the furthest along any AI-native drug programme

MindRank, a Hangzhou drug developer built around AI, says its lead candidate went from programme initiation to Phase III trials in roughly four and a half years on about $23mn of cumulative research spending. If that holds up, it is the most concrete answer yet to a question the sector has been asking loudly and […]
This story continues at The Next Web